Warnex Inc.

Warnex Inc.

September 23, 2008 07:00 ET

Warnex's Medical Laboratories Division Receives ISO Accreditation

Launches Immigration and Forensic DNA Testing

LAVAL, QUEBEC--(Marketwire - Sept. 23, 2008) - Warnex Inc. (TSX:WNX) announced today that its Medical Laboratories division has obtained ISO accreditation by the Standards Council of Canada (SCC) and has launched its DNA identification testing services for immigration and forensic purposes.

"We are pleased to have received ISO accreditation for our medical laboratories, which demonstrates our commitment to the highest level of quality," said Mark Busgang, President and CEO of Warnex. "With this accreditation, we are now launching our PRO-DNA™ Immigration Tests as well as forensic testing, allowing us to expand our DNA identification market. We are currently the only Quebec-based laboratory recognized by Citizenship and Immigration Canada to perform DNA identification tests for immigration purposes."

DNA identification tests are used to establish identity and/or parentage. They represent an invaluable tool in cases involving the reunification of immigrants with their families by offering the ultimate proof of the existence of family relationships. DNA analysis is also used as evidence in criminal investigations by making it possible to establish with certainty whether there is match between biological evidence and a given individual.

Warnex Medical Laboratories is accredited by the SCC under ISO 17025/CAN-P-4E and CAN-P-1578 for DNA analysis.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex's analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.


Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, liquidity risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information